Spero Therapeutics (SPRO) Tops Q4 EPS by 73c, Beats on Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. SPCX
10. SPY

Go back to Spero Therapeutics (SPRO) Tops Q4 EPS by 73c, Beats on Revenue

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

March 26, 2026 4:05 PM EDT

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Speros licensing partner, GSK announced the FDA had set the PDUFA date as June 18, 2026 Spero estimates cash and cash equivalents as of December 31, 2025 are sufficient to fund current operations into 2028

CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) --... More